DOI 10.1080/17520363.2026.2712925
Inflammatory burden index and prognostic outcomes in gastrointestinal cancer: a meta-analysis.
Аннотация
BACKGROUND
The Inflammatory Burden Index (IBI) has been identified as a significant prognostic factor in various gastrointestinal (GI) malignancies. However, despite extensive research, its prognostic value remains inconsistent. To clarify this association, we conducted a systematic meta-analysis following rigorous methodological standards.
METHODS
A comprehensive literature search was performed across PubMed, Web of Science, Embase, Scopus, and Cochrane databases. Ultimately, nine studies were included, covering multiple gastrointestinal cancer subtypes.
RESULTS
Our analysis demonstrated that an elevated IBI was significantly associated with poorer overall survival (OS) (HR = 2.14, 95% CI: 1.38-3.31, p = 0.001), disease-free survival (DFS) (HR = 1.75, 95% CI: 1.35-2.26, p < 0.001), and recurrence-free survival (RFS) (HR = 2.15, 95% CI: 1.59-2.92, p < 0.001). Furthermore, IBI levels were significantly correlated with several key clinicopathological factors including age, tumor size, lymph node metastases, lymph-vascular invasion, and neoadjuvant chemotherapy.
CONCLUSION
This meta-analysis suggests that elevated IBI might be a robust predictor for poor survival in GI cancer patients and correlates closely with advanced disease features including larger tumor size, lymph node metastases, and lymph-vascular invasion. These findings underscore IBI as a clinically relevant prognostic biomarker for GI malignancies.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.